Minerva Neurosciences, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Minerva Neurosciences, Inc. (NERV) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-07
- Minerva Neurosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.27M, a 662.14% increase year-over-year.
- Minerva Neurosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $8.71M, a 2830.50% increase year-over-year.
- Minerva Neurosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $272.90K, a 11.31% decline year-over-year.
- Minerva Neurosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $298.22K, a 9.44% decline year-over-year.
- Minerva Neurosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $1.33M, a 0.14% increase from fiscal 2024.
- Minerva Neurosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.33M, a 32.66% decline from fiscal 2023.
- Minerva Neurosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.97M, a 52.09% decline from fiscal 2022.
- Minerva Neurosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $4.11M, a 21.27% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.27M 10-Q · filed 2026-08-07 | $10.98M derived: sum of 2 quarters · filed 2026-08-07 | ||
| 2026-03-31 | $8.71M 10-Q · filed 2026-08-07 | |||
| 2025-12-31 | $1.33M 10-K · filed 2026-03-11 | |||
| 2025-09-30 | $272.90K 10-Q · filed 2025-11-05 | $571.12K derived: sum of 2 quarters · filed 2026-08-07 | $868.34K derived: sum of 3 quarters · filed 2026-08-07 | |
| 2025-06-30 | $298.22K 10-Q · filed 2026-08-07 | $595.45K derived: sum of 2 quarters · filed 2026-08-07 | ||
| 2025-03-31 | $297.23K 10-Q · filed 2026-08-07 | |||
| 2024-12-31 | $1.33M 10-K · filed 2026-03-11 | |||
| 2024-09-30 | $307.71K 10-Q · filed 2025-11-05 | $637.03K derived: sum of 2 quarters · filed 2025-11-05 | $1.08M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | $329.32K 10-Q · filed 2025-11-05 | $768.17K derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | $438.85K 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $1.97M 10-K · filed 2025-02-25 | |||
| 2023-09-30 | $371.94K 10-Q · filed 2024-11-05 | $980.86K derived: sum of 2 quarters · filed 2024-11-05 | $1.36M derived: sum of 3 quarters · filed 2024-11-05 | |
| 2023-06-30 | $608.91K 10-Q · filed 2024-11-05 | $985.37K derived: sum of 2 quarters · filed 2024-11-05 | ||
| 2023-03-31 | $376.46K 10-Q · filed 2024-11-05 | |||
| 2022-12-31 | $4.11M 10-K · filed 2024-02-22 | |||
| 2022-09-30 | $1.04M 10-Q · filed 2023-11-07 | $2.11M derived: sum of 2 quarters · filed 2023-11-07 | $3.16M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $1.07M 10-Q · filed 2023-11-07 | $2.12M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $1.05M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $5.22M 10-K · filed 2023-03-08 | |||
| 2021-09-30 | $1.11M 10-Q · filed 2022-11-09 | $2.50M derived: sum of 2 quarters · filed 2022-11-09 | $4.01M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $1.38M 10-Q · filed 2022-11-09 | $2.90M derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $1.52M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $9.70M 10-K · filed 2022-03-01 | |||
| 2020-09-30 | $2.06M 10-Q · filed 2021-11-08 | $5.54M derived: sum of 2 quarters · filed 2021-11-08 | $7.74M derived: sum of 3 quarters · filed 2021-11-08 | |
| 2020-06-30 | $3.49M 10-Q · filed 2021-11-08 | $5.68M derived: sum of 2 quarters · filed 2021-11-08 | ||
| 2020-03-31 | $2.20M 10-Q · filed 2021-11-08 | |||
| 2019-12-31 | $9.17M 10-K · filed 2021-03-08 | |||
| 2019-09-30 | $2.22M 10-Q · filed 2020-11-02 | $4.54M derived: sum of 2 quarters · filed 2020-11-02 | $7.00M derived: sum of 3 quarters · filed 2020-11-02 | $8.91M derived: sum of 4 quarters · filed 2020-11-02 |
| 2019-06-30 | $2.32M 10-Q · filed 2020-11-02 | $4.78M derived: sum of 2 quarters · filed 2020-11-02 | $6.69M derived: sum of 3 quarters · filed 2020-11-02 | $8.95M derived: sum of 4 quarters · filed 2020-11-02 |
| 2019-03-31 | $2.46M 10-Q · filed 2020-11-02 | $4.37M derived: sum of 2 quarters · filed 2020-11-02 | $6.63M derived: sum of 3 quarters · filed 2020-11-02 | $8.53M derived: sum of 4 quarters · filed 2020-11-02 |
| 2018-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $4.17M derived: sum of 2 quarters · filed 2020-03-09 | $6.07M derived: sum of 3 quarters · filed 2020-03-09 | $8.18M 10-K · filed 2020-03-09 |
| 2018-09-30 | $2.26M 10-Q · filed 2019-11-04 | $4.16M derived: sum of 2 quarters · filed 2019-11-04 | $6.27M 10-Q · filed 2018-11-05 | $7.53M derived: sum of 4 quarters · filed 2019-11-04 |
| 2018-06-30 | $1.90M 10-Q · filed 2019-11-04 | $4.01M 10-Q · filed 2018-08-02 | $5.27M derived: sum of 3 quarters · filed 2019-11-04 | $6.50M derived: sum of 4 quarters · filed 2019-11-04 |
| 2018-03-31 | $2.11M 10-Q · filed 2019-11-04 | $3.37M derived: sum of 2 quarters · filed 2019-11-04 | $4.61M derived: sum of 3 quarters · filed 2019-11-04 | $5.84M derived: sum of 4 quarters · filed 2019-11-04 |
| 2017-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $2.49M derived: sum of 2 quarters · filed 2019-03-12 | $3.72M derived: sum of 3 quarters · filed 2019-03-12 | $5.03M 10-K · filed 2019-03-12 |
| 2017-09-30 | $1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $2.47M derived: sum of 2 quarters · filed 2018-11-05 | $3.78M 10-Q · filed 2018-11-05 | $4.79M derived: sum of 4 quarters · filed 2018-11-05 |
| 2017-06-30 | $1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $2.54M 10-Q · filed 2018-08-02 | $3.55M derived: sum of 3 quarters · filed 2018-08-02 | $4.49M derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-03-31 | $1.31M 10-Q · filed 2018-05-03 | $2.32M derived: sum of 2 quarters · filed 2018-05-03 | $3.26M derived: sum of 3 quarters · filed 2018-05-03 | $4.09M derived: sum of 4 quarters · filed 2018-05-03 |
| 2016-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $1.95M derived: sum of 2 quarters · filed 2018-03-12 | $2.78M derived: sum of 3 quarters · filed 2018-03-12 | $3.57M 10-K · filed 2018-03-12 |
| 2016-09-30 | $935.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-06 | $1.77M derived: sum of 2 quarters · filed 2017-11-06 | $2.56M 10-Q · filed 2017-11-06 | $3.25M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-06-30 | $832.77K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $1.62M 10-Q · filed 2017-08-03 | $2.31M derived: sum of 3 quarters · filed 2018-03-12 | $2.94M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-03-31 | $790.23K 10-Q · filed 2017-05-04 | $1.48M derived: sum of 2 quarters · filed 2018-03-12 | $2.11M derived: sum of 3 quarters · filed 2018-03-12 | $2.66M derived: sum of 4 quarters · filed 2018-03-12 |
| 2015-12-31 | $691.47K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $1.32M derived: sum of 2 quarters · filed 2018-03-12 | $1.87M derived: sum of 3 quarters · filed 2018-03-12 | $2.20M 10-K · filed 2018-03-12 |
| 2015-09-30 | $628.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $1.17M derived: sum of 2 quarters · filed 2016-11-03 | $1.51M 10-Q · filed 2016-11-03 | $3.76M derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-06-30 | $545.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $882.30K 10-Q · filed 2016-08-04 | $3.13M derived: sum of 3 quarters · filed 2017-03-13 | $4.03M derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-03-31 | $336.37K 10-Q · filed 2015-05-07 | $2.58M derived: sum of 2 quarters · filed 2017-03-13 | $3.49M derived: sum of 3 quarters · filed 2017-03-13 | |
| 2014-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | $3.15M derived: sum of 2 quarters · filed 2017-03-13 | $7.42M 10-K · filed 2017-03-13 | |
| 2014-09-30 | $903.07K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $5.18M 10-Q · filed 2014-11-06 | ||
| 2014-06-30 | $4.27M 10-Q · filed 2014-08-07 | |||
| 2013-12-31 | $423.19K 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |